RotaTeq (sanofi pasteur/Wistar Institute/Children's Hospital of Philadelphia).

Abstract

Sanofi pasteur MSD (a joint venture between Merck & Co and sanofi pasteur (formerly Aventis Pasteur)), in collaboration with the Wistar Institute and the Children's Hospital of Philadelphia, is developing RotaTeq, an oral liquid pentavalent vaccine for the potential prevention of rotavirus infection-related disorders, such as infant diarrhea and malabsorption. Phase III trials had commenced by March 2001.

• Authors: Ulrich Desselberger
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 6 Issue 2 Pg. 199-208 (Feb 2005) ISSN: 1472-4472 [Print] England
• PMID: 15751744 (Publication Type: Journal Article, Review)

Chemical References

• RotaTeq
• Rotavirus Vaccines
• Vaccines, Attenuated

Topics

• Clinical Trials, Phase II as Topic
• Contraindications
• Humans
• Rotavirus Infections (prevention & control)
• Rotavirus Vaccines (adverse effects, chemical synthesis, therapeutic use)
• Structure-Activity Relationship
• Vaccines, Attenuated (adverse effects, chemical synthesis, therapeutic use)